Charles River Laboratories acquires Agilux Laboratories, Inc.
13 October 2016 | By Charles River Laboratories
Enhances Charles River’s early-stage capabilities in bioanalytical services...
List view / Grid view
13 October 2016 | By Charles River Laboratories
Enhances Charles River’s early-stage capabilities in bioanalytical services...
6 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The grant from the MJFF therapeutic pipeline program will support studies for the optimisation of molecules to provide preclinical proof of concept in...
4 October 2016 | By Cisbio
Cisbio Bioassays has developed several assays for covering all the needs for monitoring kinase targets...
Integrating the S3e™ Cell Sorter into sample preparation upstream of the QX200™ Droplet Digital System provided details about cell subpopulations that would have been undetectable in heterogeneous populations...
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Tuberculosis is the most deadly infectious disease in the world. Standard TB therapy takes at least 6 months and patients infected with multi-drug...
27 September 2016 | By Quotient Clinical
Department moves into enhanced facility and increases headcount in response to continued demand for services...
26 September 2016 | By Charles River Laboratories
Partnership intends to accelerate translation of discoveries into novel therapies for patients...
21 September 2016 | By Abcam
PD-L1 [28-8] (ab205921) is an ideal tool to quantify PD-L1 expression in patients for PD-1 based therapies....
20 September 2016 | By Drug Target Review
In this Hit-To-Lead In-Depth Focus: Hit-to-lead in drug discovery; Zebrafish early-life stages as neurological screening and detection tools...
13 September 2016 | By SMi
SMi Reports (13.09. 2016, London, UK): Alexion, BioMarin, Chiesi, MHRA, NICE to meet in London in October to discuss updates in the orphan drug landscape...
Unforeseen efficacy and safety-related issues with drugs continue to be a major cause of their attrition, despite significant efforts that are expended to eliminate them prior to initiating clinical trials...
Starting in the 1970s, the drug discovery research process changed dramatically. Our understanding of biological targets and pathways grew and the largely empirical and target agnostic in vivo pharmacology approach was replaced with target-centric methods...
10 August 2016 | By Charles River Laboratories
Charles River Laboratories announced that it has entered into a strategic partnership with the Milner Therapeutics Institute and Consortium...
4 August 2016 | By Bio-Rad Laboratories
The CFX96™ Optical Reaction Module converts the C1000 Touch™ Thermal Cycler chassis into the powerful and precise CFX96 Touch Real-Time PCR Detection System...
21 July 2016 | By SMi Group
SMi's 5th annual Cancer Vaccines event will showcase 5 key spotlight sessions on the latest advances in vaccine development and cancer therapy breakthroughs when it returns to Central London this autumn...